Costs and outcomes of recombinant human bone morphogenetic protein-2 usage in single-level posterior or transforaminal lumbar interbody fusion in a propensity score-matched national, retrospective cohort
Elsevier ·
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Costs and outcomes of recombinant human bone morphogenetic protein-2 usage in single-level posterior or transforaminal lumbar interbody fusion in a propensity score-matched national, retrospective cohort. // The Spine Journal. – URL: https://www.sciencedirect.com/science/article/pii/S1529943026006698?dgcid=rss_sd_all
Costs and outcomes of recombinant human bone morphogenetic protein-2 usage in single-level posterior or transforaminal lumbar interbody fusion in a propensity score-matched national, retrospective cohort. The Spine Journal. https://www.sciencedirect.com/science/article/pii/S1529943026006698?dgcid=rss_sd_all
“Costs and outcomes of recombinant human bone morphogenetic protein-2 usage in single-level posterior or transforaminal lumbar interbody fusion in a propensity score-matched national, retrospective cohort.” The Spine Journal.
@article{article69364,
title = {Costs and outcomes of recombinant human bone morphogenetic protein-2 usage in single-level posterior or transforaminal lumbar interbody fusion in a propensity score-matched national, retrospective cohort},
journal = {The Spine Journal},
url = {https://www.sciencedirect.com/science/article/pii/S1529943026006698?dgcid=rss_sd_all}
}